Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial

Ari Green(University of California, San Francisco), Jeffrey M. Gelfand(University of California, San Francisco), Bruce Cree(University of California, San Francisco), Carolyn Bevan(University of California, San Francisco), W. John Boscardin(University of California, San Francisco), Feng Mei(University of California, San Francisco), Justin Inman(University of California, San Francisco), Sam Arnow(University of California, San Francisco), Michael Devereux(University of California, San Francisco), Aya Abounasr(University of California, San Francisco), Hiroko Nobuta(Broad Institute), Alyssa H. Zhu(University of California, San Francisco), Matt Friessen(University of California, San Francisco), Roy Gerona(University of California, San Francisco), H.‐Christian von Büdingen(University of California, San Francisco), Roland G. Henry(University of California, San Francisco), Stephen L. Hauser(University of California, San Francisco), Jonah R. Chan(University of California, San Francisco)
The Lancet
October 13, 2017
Cited by 570Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis